Aviva’s Gilead Sciences GILD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$150M Buy
1,183,858
+9,282
+0.8% +$1.22M 0.22% 81
2026
Q1
$164M Buy
1,174,576
+17,838
+2% +$2.5M 0.27% 66
2025
Q4
$142M Buy
1,156,738
+59,782
+5% +$7.27M 0.24% 79
2025
Q3
$122M Buy
1,096,956
+56,151
+5% +$6.38M 0.22% 89
2025
Q2
$115M Sell
1,040,805
-159,954
-13% -$17M 0.24% 85
2025
Q1
$135M Buy
1,200,759
+106,212
+10% +$11M 0.32% 55
2024
Q4
$101M Sell
1,094,547
-54,085
-5% -$4.87M 0.26% 74
2024
Q3
$96.3M Buy
1,148,632
+2,308
+0.2% +$176K 0.25% 80
2024
Q2
$78.6M Buy
1,146,324
+240,384
+27% +$16M 0.22% 89
2024
Q1
$66.4M Buy
905,940
+39,455
+5% +$3.03M 0.22% 89
2023
Q4
$70.2M Buy
866,485
+66,226
+8% +$5.15M 0.25% 78
2023
Q3
$60M Buy
800,259
+13,074
+2% +$1.01M 0.25% 72
2023
Q2
$60.7M Buy
787,185
+68,380
+10% +$5.45M 0.25% 76
2023
Q1
$59.6M Buy
718,805
+95,443
+15% +$7.91M 0.27% 63
2022
Q4
$53.5M Buy
623,362
+105,121
+20% +$8.32M 0.26% 69
2022
Q3
$32M Sell
518,241
-19,547
-4% -$1.23M 0.18% 121
2022
Q2
$33.2M Buy
537,788
+117,295
+28% +$7.26M 0.18% 120
2022
Q1
$25M Buy
420,493
+19,418
+5% +$1.24M 0.13% 181
2021
Q4
$29.1M Sell
401,075
-54,237
-12% -$3.74M 0.12% 166
2021
Q3
$31.8M Buy
455,312
+8,447
+2% +$593K 0.14% 147
2021
Q2
$30.8M Buy
446,865
+27,639
+7% +$1.85M 0.14% 160
2021
Q1
$27.1M Sell
419,226
-383
-0.1% -$24.7K 0.13% 158
2020
Q4
$24.4M Buy
419,609
+14,026
+3% +$846K 0.13% 160
2020
Q3
$25.6M Sell
405,583
-14,141
-3% -$981K 0.15% 123
2020
Q2
$32.3M Sell
419,724
-28,878
-6% -$2.21M 0.2% 100
2020
Q1
$33.5M Buy
448,602
+270
+0.1% +$18.7K 0.25% 87
2019
Q4
$29.1M Sell
448,332
-2,361
-0.5% -$154K 0.18% 114
2019
Q3
$28.6M Sell
450,693
-133,845
-23% -$8.75M 0.19% 113
2019
Q2
$39.5M Sell
584,538
-12,161
-2% -$800K 0.27% 82
2019
Q1
$38.8M Sell
596,699
-5,423
-0.9% -$360K 0.26% 93
2018
Q4
$37.7M Sell
602,122
-138,139
-19% -$9.66M 0.28% 91
2018
Q3
$57.2M Sell
740,261
-26,254
-3% -$1.98M 0.31% 83
2018
Q2
$54.3M Sell
766,515
-10,705
-1% -$756K 0.32% 78
2018
Q1
$58.6M Sell
777,220
-62,528
-7% -$4.97M 0.36% 70
2017
Q4
$60.2M Sell
839,748
-104,966
-11% -$7.97M 0.34% 69
2017
Q3
$76.5M Buy
944,714
+12,850
+1% +$983K 0.41% 54
2017
Q2
$66M Buy
931,864
+4,340
+0.5% +$289K 0.37% 60
2017
Q1
$63M Sell
927,524
-34,573
-4% -$2.43M 0.36% 63
2016
Q4
$68.9M Sell
962,097
-76,794
-7% -$5.71M 0.41% 53
2016
Q3
$82.2M Buy
1,038,891
+141,685
+16% +$11.5M 0.51% 43
2016
Q2
$74.8M Sell
897,206
-45,473
-5% -$4.04M 0.51% 46
2016
Q1
$86.6M Sell
942,679
-189,414
-17% -$17.1M 0.64% 33
2015
Q4
$115M Buy
1,132,093
+134,385
+13% +$14M 0.87% 17
2015
Q3
$98M Sell
997,708
-82,792
-8% -$9.2M 0.81% 17
2015
Q2
$127M Sell
1,080,500
-63,967
-6% -$6.99M 0.89% 14
2015
Q1
$112M Buy
1,144,467
+351,918
+44% +$35.7M 0.77% 20
2014
Q4
$74.7M Buy
792,549
+55,165
+7% +$5.71M 0.58% 35
2014
Q3
$78.5M Sell
737,384
-1,651
-0.2% -$162K 0.62% 31
2014
Q2
$61.3M Buy
739,035
+400
+0.1% +$31.1K 0.47% 47
2014
Q1
$52.3M Sell
738,635
-57,941
-7% -$4.54M 0.42% 54
2013
Q4
$59.9M Sell
796,576
-157,261
-16% -$11M 0.5% 45
2013
Q3
$59.9M Buy
953,837
+90,388
+10% +$5.4M 0.53% 41
2013
Q2
$44.2M Buy
+863,449
New +$45M 0.45% 48

Other funds holding GILD

Aviva's GILD Position: Q2 2026 in Review

Aviva increased its Gilead Sciences (GILD) stake by 0.79% in Q2 2026, buying an estimated $1.22M and bringing the position to 1,183,858 shares worth $150M. The position accounts for 0.22% of the portfolio, ranked #81.

Aviva first reported a position in GILD in Q2 2013 and has held it in 53 quarters since. The position peaked at $164M in Q1 2026. 2,268 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • Aviva held 1,183,858 shares of Gilead Sciences worth $150M as of Q2 2026.
  • Aviva bought 9,282 Gilead Sciences shares in Q2 2026, an estimated $1.22M.
  • Gilead Sciences made up 0.22% of Aviva's portfolio in Q2 2026, its #81 holding.
  • Aviva first reported a position in Gilead Sciences in Q2 2013 and has held it in 53 quarters since.
  • Aviva's Gilead Sciences position peaked at $164M in Q1 2026.
  • 2,268 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Aviva's 13F filing for Q2 2026, filed 13 Aug 2026.